Drug-resistant tuberculosis (TB) is estimated to cause 13% of all antimicrobial resistance-
attributable deaths worldwide and is driven by both ongoing resistance acquisition and …

Tuberculosis (TB) is among the most difficult infections to treat, requiring several months of
multidrug therapy to produce a durable cure. The reasons necessitating long treatment times …

The increasing incidence of drug resistance in Mycobacterium tuberculosis has diminished
the efficacy of almost all available antibiotics, complicating efforts to combat the spread of …

Page 1 Catalogue of mutations in Mycobacterium tuberculosis complex and their
association with drug resistance Second edition Page 2 Page 3 Catalogue of mutations in …

Background Mycobacterium tuberculosis whole-genome sequencing (WGS) has been
widely used for genotypic drug susceptibility testing (DST) and outbreak investigation. For …

Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to the first-line drugs
isoniazid and rifampin, is a growing source of global mortality and threatens global control of …

The emergence of multidrug-resistant Gram-negative bacteria underscores the need to
define genetic vulnerabilities that can be therapeutically exploited. The Gram-negative …

The success of Mycobacterium tuberculosis (Mtb) is largely attributed to its ability to
physiologically adapt and withstand diverse localized stresses within host …

First achieved in 1998 by Cole et al., the complete genome sequence of Mycobacterium
tuberculosis continues to provide an invaluable resource to understand tuberculosis (TB) …

Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …